Cancer Stem Cells and Epigenetic Regulation: A Survey

Abstract

This survey paper delves into the intricate roles of cancer stem cells (CSCs) and their epigenetic regulation via acylation, highlighting the implications for cancer progression and therapeutic resistance. CSCs, characterized by their self-renewal and differentiation capabilities, are pivotal in tumor initiation and heterogeneity, posing significant challenges to effective cancer treatment. The paper explores how acylation, a key epigenetic modification, influences gene expression and chromatin dynamics, thereby maintaining CSC properties and promoting tumorigenesis. The interplay between CSCs and the tumor microenvironment, particularly metabolic reprogramming, is examined, emphasizing the regulatory role of lipid metabolism and its potential as a therapeutic target. The survey also addresses the significance of targeting CSCs and their microenvironment, proposing strategies that integrate epigenetic and metabolic interventions to enhance therapeutic efficacy. By elucidating these complex mechanisms, the paper aims to advance the understanding of CSC dynamics and contribute to the development of more effective cancer therapies. Emerging research areas and unanswered questions are highlighted, underscoring the need for continued investigation into CSC biology and the development of innovative treatment strategies.

1 Introduction

1.1 Significance of Cancer Stem Cells

Cancer stem cells (CSCs) are pivotal in cancer biology, influencing tumor initiation, progression, and resistance to therapies. These cells exhibit self-renewal and differentiation capabilities, sustaining tumor heterogeneity. The CSC hypothesis suggests that a specific subpopulation within tumors possesses stem-like properties, enabling tumor growth and therapeutic resistance. This characteristic complicates effective cancer treatment, as conventional therapies often overlook CSCs, leading to metastasis and recurrence. Understanding CSC behavior and their interactions with the tumor microenvironment is essential for developing targeted therapies to improve clinical outcomes [1, 2, 3].

CSCs significantly contribute to tumor progression and metastasis across various cancers, including colorectal cancer, where they are integral to tumor initiation and therapy resistance [4]. Their phenotypic plasticity allows adaptation to microenvironmental changes, evasion of therapies, and promotion of tumor recurrence, further enhanced by metabolic alterations such as cholesterol metabolism [5].

The tumor microenvironment critically influences CSC behavior, affecting tumorigenesis and progression [6]. Understanding the complex interactions between CSCs and their microenvironment is vital for developing strategies to eliminate these resilient cells and overcome treatment resistance [7]. By elucidating the molecular mechanisms governing CSC behavior, researchers can create innovative therapies targeting CSCs, thereby improving treatment outcomes and reducing relapse rates [2].



Figure 1: chapter structure

1.2 Role of Epigenetic Regulation

Epigenetic regulation is crucial in modulating CSC behavior, with acylation being a key mechanism influencing gene expression and chromatin structure. Acylation, including histone and non-histone protein acetylation, modifies chromatin architecture, regulating transcription and maintaining CSC properties. This is particularly significant in hepatocellular carcinoma (HCC), where histone acetylation promotes cancer progression by modulating CSC traits [8].

The complexity of acylation is heightened by short-chain lysine acylations, which add regulatory nuances to the gene expression network in CSCs [8]. These modifications are vital for the metabolic reprogramming of CSCs, enabling adaptation and survival in the tumor microenvironment [2]. Environmental factors like hypoxia and inflammation further shape CSC behavior, emphasizing the tumor microenvironment's role in epigenetic regulation [9].

The interplay between epigenetic regulation and metabolic reprogramming is crucial for CSC functionality, impacting gene expression and oncogenesis [10]. This relationship is evident in liver CSCs, where intrinsic and extrinsic factors mediate therapy resistance, necessitating a comprehensive understanding of these pathways [4]. Studying DNA methylation and histone modifications is essential for developing strategies to target CSCs and prevent cancer recurrence.

Targeting epigenetic pathways, including the Notch signaling cascade, offers a promising approach for inhibiting CSCs and reducing cancer relapse potential [2]. Understanding epigenetic regulation mechanisms is vital for developing effective cancer therapies. Disrupting these control mechanisms can impair CSCs' tumor-sustaining abilities and therapeutic resistance, enhancing treatment efficacy and patient outcomes. Integrating omic data into regulatory networks is crucial for elucidating these processes, providing insights into CSC biology and potential therapeutic targets [11].

1.3 Objectives of the Paper

This survey paper aims to elucidate the critical role of CSCs in tumor initiation, progression, and metastasis, addressing knowledge gaps regarding their mechanisms and interactions within the tumor microenvironment [3]. A primary objective is to explore the dynamic nature of CSCs and their interactions with the microenvironment, crucial for enhancing targeting strategies in cancer therapy [2]. The survey specifically focuses on intra-tumor heterogeneity and the role of CSCs in this phenomenon [10].

Additionally, the paper investigates drug resistance mechanisms in cancer therapy, emphasizing CSCs' role in this process [7]. It proposes a therapeutic approach using a differentiating agent to promote CSC differentiation into non-cancerous cells, aiming to eliminate residual cancer cells and improve treatment outcomes [12]. The need for innovative techniques, such as detecting circulating tumor cells and exosomes, is also highlighted to advance personalized medicine [13].

Through these objectives, the paper aspires to enhance the understanding of CSC dynamics, epigenetic regulation, and cancer metabolism, ultimately contributing to the development of more effective cancer therapies [11].

1.4 Structure of the Survey

This survey is structured to provide a comprehensive examination of CSCs and their role in cancer biology, focusing on epigenetic regulation and therapeutic strategies. The introduction underscores the significance of CSCs in cancer research, leading to a detailed exploration of their impact on tumor progression and treatment resistance [14]. Subsequent sections cover foundational concepts of CSCs, including definitions, historical context, identification methods, and implications in cancer therapy [15].

Later sections delve into the interplay between epigenetic mechanisms and signaling pathways regulating CSC properties, establishing a framework for understanding these complex interactions [16]. The analysis includes phenotypic attributes and molecular mechanisms driving CSC behavior, emphasizing metabolic pathways and their therapeutic implications.

The survey also addresses critical aspects of cancer metabolism and lipid modifications, examining their contributions to cancer progression and potential as therapeutic targets. It discusses the metabolic interactions between cancer cells and the tumor microenvironment, highlighting p53's role in regulating cancer metabolism. Specifically, it details how p53 shifts the metabolic reliance from glycolysis to oxidative phosphorylation (OXPHOS), influencing cancer cell proliferation, invasion, and therapy resistance. This regulatory function is crucial for promoting apoptosis post-chemotherapy and modulating metabolic pathways contributing to treatment resistance, particularly with p53 mutations. The role of ubiquitination and deubiquitination in metabolic reprogramming further underscores the complexity of cancer metabolism as a therapeutic target [17, 18].

In later sections, the focus shifts to identifying potential therapeutic targets and strategies, emphasizing the promise of targeting epigenetic modifications, lipid metabolism, and the tumor microenvironment. The survey concludes with a discussion on emerging research areas and future directions in cancer treatment, highlighting the integration of innovative technologies such as microfluidic platforms and 3D tumor models to enhance personalized medicine [13]. This organized approach aims to advance the understanding of CSC dynamics and contribute to developing more effective cancer therapies [12].The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Cancer Stem Cell Characteristics and Identification

Cancer stem cells (CSCs) are pivotal in tumor biology due to their self-renewal and differentiation capabilities, contributing to tumor heterogeneity and oncogenesis [7]. Their phenotypic plasticity, regulated by intricate signaling networks like the Wnt pathways, enables adaptation to diverse microenvironments, complicating their identification and therapeutic targeting [11]. This plasticity exacerbates cancer heterogeneity, challenging effective treatment due to varied responses.

CSCs are identified using specific markers and isolation techniques. In breast cancer, CD44 and CD24 are critical markers for identifying breast cancer stem cells (BCSCs) [19]. Colorectal cancer studies emphasize unique phenotypic traits and drug resistance mechanisms of CSCs [4]. The indefinability of CSCs, shaped by the tumor's stress-history, complicates their characterization [9].

CSCs possess enhanced DNA repair, cellular plasticity, and immune evasion capabilities, hindering their identification and targeting. Their adaptability is further demonstrated by metabolic reprogramming, modifying pathways for proliferation and survival within the tumor microenvironment [12]. Understanding these complexities is essential for developing strategies to eradicate CSCs and improve cancer treatment outcomes. Despite advancements in CSC identification, challenges persist, particularly in tumors lacking distinct oncogenes or driven by tumor suppressor gene inactivation, complicating the identification of targetable genes [12].

2.2 Epigenetic Regulation and Acylation Mechanisms

Epigenetic regulation via acylation significantly influences CSC behavior by modulating gene expression, chromatin architecture, and cellular phenotype. Acylation encompasses post-translational modifications such as acetylation, succinylation, and myristoylation, each uniquely impacting cellular processes [8]. Acetylation, particularly of histone and non-histone proteins, plays a pivotal role in transcriptional regulation and chromatin remodeling, altering transcriptional machinery accessibility to DNA and influencing gene expression patterns vital for maintaining CSC properties [8].

Regulatory pathways integral to acylation mechanisms, notably Wnt/-catenin and STAT3, are crucial for understanding CSC epigenetic regulation [8]. Histone acetylation, especially H3K4ac, targeted by SIRT1 in breast cancer, underscores subtype-specific regulation of histone modifications and their implications for CSC behavior [8]. The interplay between acetylation and other epigenetic marks, such as methylation, complicates regulatory networks governing CSCs, necessitating comprehensive approaches to dissect these interactions [8].

Short-chain lysine acylations, including propionylation and butyrylation, introduce further regulatory complexity, expanding the landscape of gene expression modulation [8]. These modifications are critical for CSC metabolic reprogramming, aiding adaptation and survival in the tumor microenvironment [8]. Protein acetylation and deacetylation, particularly involving histone deacetylases (HDACs), contribute to hepatocellular carcinoma (HCC) initiation and progression [8].

Non-histone protein acylations, such as myristoylation, also play a significant role in regulating CSC properties by affecting protein stability, localization, and interactions, thereby influencing pathways crucial for CSC maintenance and tumor progression [8]. Understanding these mechanisms is vital for developing targeted therapies that disrupt the epigenetic control of CSCs, potentially overcoming treatment resistance and reducing cancer recurrence likelihood [7]. By elucidating the intricate networks of acylation in epigenetic regulation, researchers can identify novel therapeutic targets and strategies to combat CSC-driven malignancies [8].

2.3 Tumor Microenvironment and Intercellular Interactions

The tumor microenvironment (TME) profoundly influences CSC behavior, playing a crucial role in tumor progression and therapy resistance. Comprising various nonmalignant cells like adipocytes, fibroblasts, and immune cells, the TME interacts with tumor cells to create a supportive niche for CSCs [6]. These interactions facilitate genetic and proteomic exchanges, enhancing CSC adaptability and survival under diverse microenvironmental conditions.

Exosomes are key mediators of intercellular communication within the TME, influencing CSC behavior and contributing to cancer progression and metastasis. They transport proteins, lipids, and nucleic acids between CSCs and other cells, modulating the TME and promoting CSC survival [20]. This molecular exchange is crucial for maintaining CSC plasticity and resilience, enabling evasion of immune surveillance and adaptation to therapeutic pressures.

The TME presents challenges such as nutrient depletion and metabolic heterogeneity, requiring CSCs to undergo metabolic adaptations for survival [21]. Competition for nutrients between tumor and immune cells can lead to immune cell metabolic exhaustion, impairing antitumor activity and complicating therapeutic strategies [21]. Understanding the interplay between CSCs and their microenvironment is essential for developing effective targeting strategies against these resilient cells.

Despite the TME's critical role in cancer progression, the precise mechanisms of CSC interactions with other cells within this environment remain incompletely understood. Bidirectional interactions between CSCs and their niches enhance drug resistance, highlighting the need for a comprehensive understanding of these dynamics for targeted therapy development [22]. By elucidating the complex interplay between CSCs and the TME, researchers can identify novel therapeutic targets and strategies to overcome treatment resistance and improve cancer treatment outcomes.

3 Epigenetic Regulation through Acylation

3.1 Mechanisms of Acylation in Epigenetic Regulation

Acylation, a key post-translational modification, significantly influences the epigenetic regulation of cancer stem cells (CSCs) by modulating gene expression and chromatin dynamics. This process is governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), which modify lysine residues on histone proteins, thereby altering chromatin structure and accessibility [2, 7]. The balance between HATs and HDACs is crucial for maintaining chromatin state, essential for gene expression patterns vital for CSC maintenance and tumorigenesis [7].

Histone acetylation facilitates transcriptional activation by neutralizing lysine residues' positive charge, resulting in a relaxed chromatin conformation that enhances accessibility for transcription factors and RNA polymerase, promoting active gene transcription [9]. This regulation maintains gene expression homeostasis in CSCs, where dysregulation can lead to aberrant gene expression and cancer progression [4].

Beyond histone acetylation, acylation modifications like succinylation, butyrylation, and propionylation add complexity to gene regulation by influencing chromatin remodeling and interacting with other epigenetic marks, integral to CSC metabolic reprogramming for adaptation and survival in the tumor microenvironment [6]. The interplay among different acylation types and their integration into broader epigenetic networks underscores the intricate regulatory mechanisms governing CSC behavior and phenotypic plasticity [9].

Acylation also affects non-histone proteins involved in transcriptional regulation, DNA repair, and signal transduction, altering protein-protein interactions, stability, and subcellular localization crucial for preserving CSC characteristics and promoting tumor progression [2]. Understanding the biochemical pathways and molecular targets of acylation in epigenetic regulation is vital for developing targeted therapies that disrupt these processes, potentially overcoming treatment resistance [7]. Systems biology approaches can map complex interactions within acylation networks, providing insights into novel therapeutic targets for CSC-driven malignancies [2].



(a) The Image Represents a Comprehensive Overview of Histone Acetylation Markers[23]



(b) The image depicts a biochemical pathway involving acetyltransferases, lysine acetylation, and lysine benzoylation.[24]



(c) Metabolic Pathways and Metabolic Products[25]

Figure 2: Examples of Mechanisms of Acylation in Epigenetic Regulation

As illustrated in Figure 2, the dynamic and intricate process of epigenetic regulation through acylation significantly influences gene expression and cellular function. The diagrams exemplify the biochemical intricacies of these mechanisms, with the first image providing an overview of histone acetylation markers, detailing the diversity of histone modifications. The second image explores a biochemical pathway involving acetyltransferases and lysine modifications, while the third image elucidates metabolic pathways and their products, highlighting the interconnectedness of metabolic

processes with epigenetic mechanisms. Collectively, these examples underscore the complexity and significance of acylation in modulating epigenetic landscapes, thereby impacting cellular identity and function [23, 24, 25].

3.2 Impact on Cancer Stem Cell Behavior

Acylation plays a crucial role in shaping cancer stem cell (CSC) behavior by modulating key epigenetic pathways governing their proliferation, differentiation, and survival. This modification impacts chromatin structure and gene expression, maintaining the undifferentiated state of CSCs, essential for sustaining tumor heterogeneity and promoting resistance to conventional therapies [19]. The reversible nature of acylation-related modifications aligns with the dynamic plasticity observed in CSCs, enabling transitions between plastic and rigid phenotypes, enhancing their adaptive potential [9].

In colorectal cancer (CRC), understanding CSC roles has led to identifying therapeutic targets modulated by acylation [4]. Modulating specific signaling pathways regulated by acylation can influence CSC traits, impacting tumor growth and invasion, particularly in hepatocellular carcinoma (HCC), where targeting HDACs has been proposed to reverse tumor suppressive gene repression, highlighting acylation's therapeutic potential [9].

The phenotypic plasticity of CSCs, driven by acylation and other epigenetic modifications, supports rapid adaptation to environmental stressors, facilitating tumor growth and invasion [19]. This adaptability is illustrated by distinct invasion dynamics in tumor models, where variations in acylation lead to different outcomes, emphasizing this modification's importance in CSC behavior. Understanding the complex interactions between acylation and CSC behavior can help identify novel therapeutic targets for CSC-driven malignancies, offering hope for improved cancer treatment outcomes.

3.3 Gene Expression and Chromatin Dynamics

The interplay between acylation, gene expression, and chromatin dynamics is pivotal in regulating CSC behavior. Acylation, particularly histone acetylation, modulates chromatin architecture, influencing transcriptional activity and maintaining the undifferentiated state of CSCs [8]. This modification alters electrostatic interactions between histones and DNA, resulting in a more open chromatin conformation that facilitates the binding of transcriptional machinery [2]. Enhanced accessibility of transcription factors to DNA promotes the expression of genes essential for CSC maintenance and tumorigenesis [9].

The dynamic nature of chromatin structure, regulated by the balance between HATs and HDACs, is crucial for CSC plasticity and adaptability [7]. Dysregulation of these enzymes can lead to aberrant gene expression patterns, contributing to cancer progression and resistance to therapy [4]. The integration of acylation with other epigenetic modifications, such as methylation, complicates regulatory networks, underscoring the need for comprehensive approaches to understand these interactions [8].

Acylation also affects non-histone proteins involved in transcriptional regulation, impacting protein stability, localization, and interactions, thereby influencing pathways critical for CSC maintenance and tumor progression [8]. Understanding these complex mechanisms is essential for developing targeted therapies that can disrupt the epigenetic control of CSCs, potentially overcoming treatment resistance and reducing cancer recurrence likelihood [7]. By elucidating the intricate networks of acylation in epigenetic regulation, researchers can identify novel therapeutic targets and strategies to effectively combat CSC-driven malignancies [2].

In recent studies, the hierarchical organization of phenotypic attributes and molecular mechanisms in cancer stem cells (CSCs) has garnered significant attention, particularly regarding its implications for therapeutic strategies. This complexity is well illustrated in Figure 3, which categorizes key concepts into several interconnected domains: epigenetic modifications, CSC phenotypic plasticity, therapeutic opportunities, CSC biology, tumor microenvironment, and natural product strategies. The figure not only emphasizes the intricate interplay between these elements but also provides valuable insights into potential therapeutic interventions and future research directions, thereby enhancing our understanding of CSCs and their role in cancer progression. Such a comprehensive framework is essential for developing targeted therapies that address the unique challenges posed by CSCs.



Figure 3: This figure illustrates the hierarchical organization of phenotypic attributes and molecular mechanisms in cancer stem cells (CSCs), highlighting the interplay with metabolic pathways and therapeutic implications. It categorizes the key concepts into epigenetic modifications, CSC phenotypic plasticity, therapeutic opportunities, CSC biology, tumor microenvironment, and natural product strategies, providing insights into potential therapeutic interventions and future research directions.

4 Phenotypic Attributes and Molecular Mechanisms

4.1 Interplay with Metabolic Pathways

The intricate relationship between epigenetic modifications and metabolic pathways is pivotal in shaping cancer stem cell (CSC) behavior, with significant implications for tumor growth, therapy resistance, and cellular plasticity. Histone modifications, as key epigenetic alterations, regulate gene expression linked to metabolic pathways, facilitating the metabolic reprogramming necessary for CSC adaptation to environmental stressors [11]. This reprogramming is vital for maintaining CSC stemness and promoting tumor heterogeneity [11].

CSC phenotypic plasticity and dedifferentiation are modulated by metabolic interactions within the tumor microenvironment, allowing CSCs to transition between metabolic states, such as oxidative phosphorylation and glycolysis, to fulfill energy requirements and sustain tumorigenic potential [5]. Epigenetic regulators play a crucial role in modulating these pathways, impacting CSC survival and proliferation by either enhancing or suppressing specific metabolic routes [2].

The tumor microenvironment exerts a profound influence on CSC metabolism, with factors like hypoxia and nutrient availability shaping metabolic pathways [5]. These environmental cues can induce changes in histone modifications, thereby altering gene expression patterns that drive metabolic reprogramming in CSCs. Understanding the interaction between CSCs and their microenvironment

is essential for elucidating CSC phenotypic attributes, as demonstrated by methodologies that map these interactions [2].

Exploring the metabolic dependencies of CSCs and their epigenetic regulation offers significant therapeutic opportunities. Targeting metabolic pathways essential for CSC maintenance, alongside epigenetic modulators, could effectively disrupt CSC function and inhibit tumor growth [26]. Future research should focus on developing selective epigenetic and metabolic inhibitors to enhance cancer therapy efficacy and combat treatment resistance. By unraveling the complex interactions between epigenetic modifications and metabolic pathways, researchers can better predict tumor behavior and therapy responses, paving the way for improved treatment strategies.

4.2 Therapeutic Implications

The study of cancer stem cell (CSC) biology and its epigenetic regulation holds significant potential for developing targeted cancer therapies. Understanding the mechanisms of drug resistance in CSCs is crucial for devising effective therapeutic strategies [7]. The Wnt signaling pathway, in particular, has been identified as a critical target for overcoming therapeutic resistance, highlighting the need to elucidate these signaling mechanisms in CSCs [27]. Advances in CSC biology have shown promising preclinical and clinical outcomes in targeted therapies [28].

As illustrated in Figure 4, the therapeutic implications in cancer treatment emphasize the importance of targeting cancer stem cells (CSCs), addressing the tumor microenvironment, and utilizing natural products. Key areas highlighted in the figure include strategies to overcome drug resistance through CSC-targeted approaches, the significance of the tumor microenvironment in enhancing therapeutic outcomes, and the potential of natural products for multi-targeted interventions.

Targeting the tumor microenvironment, essential for CSC survival and drug resistance, represents a promising strategy for improving therapeutic outcomes [6]. Recognizing the niche as a vital component in CSC survival suggests that interventions targeting both CSCs and their supportive microenvironment could enhance treatment efficacy [22]. Innovative therapeutic strategies that address both cancer stem cells and the tumor microenvironment are crucial for improving patient outcomes, particularly in cancers with significant CSC involvement [4].

Natural products offer a multi-targeted approach to overcoming CSC-related drug resistance, providing alternative pathways for therapeutic intervention [29]. By leveraging the potential of natural compounds, researchers can develop strategies that disrupt CSC survival and proliferation, thereby enhancing the effectiveness of existing treatments. Moreover, integrating systems biology approaches aids in identifying novel biomarkers and therapeutic targets, paving the way for more personalized and effective cancer therapies.



Figure 4: This figure illustrates the therapeutic implications in cancer treatment, focusing on targeting cancer stem cells (CSCs), the tumor microenvironment, and the use of natural products. Key areas include overcoming drug resistance through CSC-targeted strategies, addressing the tumor microenvironment to improve therapeutic outcomes, and leveraging natural products for multi-targeted interventions.

5 Cancer Metabolism and Lipid Modification

Understanding metabolic alterations in tumor cells is crucial for crafting effective cancer therapies. The synergy of various metabolic pathways not only supports rapid cancer cell proliferation but also aids their adaptation to the tumor microenvironment. This section delves into cancer metabolism mechanisms, focusing on fundamental changes that characterize cancer cells and their contributions to tumor growth and survival, with a detailed examination of lipid metabolic pathways.

5.1 Overview of Cancer Metabolism

Cancer metabolism encompasses alterations that enable cells to thrive under nutrient scarcity and hypoxia [30]. A hallmark is the Warburg effect, where cancer cells predominantly use glycolysis for ATP production even with available oxygen [31], providing biosynthetic precursors for rapid proliferation [30]. Lipid metabolism is reprogrammed, with increased de novo fatty acid synthesis and lipid uptake to meet energy and membrane biosynthesis needs [32]. The PI3K-AKT pathway, often activated in cancers, regulates these lipid pathways, facilitating adaptation to environmental changes [30]. Enzymes involved in lipid metabolism are implicated in cancer metastasis, suggesting their potential as therapeutic targets [32].

Amino acid metabolism, especially non-essential amino acids like glutamine, is vital for biosynthesis and redox balance, supporting cancer cell metabolism [33]. The role of one-carbon metabolism in nucleotide synthesis presents further therapeutic opportunities [33]. These metabolic reprogramming events, driven by intrinsic genetic alterations and extrinsic factors like hypoxia, allow cancer cells to thrive in the tumor microenvironment [30]. Understanding these networks is key to identifying novel therapeutic strategies that disrupt cancer cells' metabolic dependencies and improve treatment outcomes [31].

5.2 Lipid Metabolic Pathways and Cancer Progression

Lipid metabolism is pivotal in cancer progression, especially for cancer stem cells (CSCs). Anabolic and catabolic lipid processes support rapid proliferation and adaptation to metabolic stress [34]. Cancer cells alter fatty acid metabolism to thrive under hypoxia and nutrient deprivation [35], crucial for maintaining CSC tumorigenic potential. The PI3K-AKT pathway is a central lipid metabolism regulator; its aberrant activation leads to metabolic dysregulation [36], allowing cancer cells to proliferate independently. Under metabolic stress, cancer cells employ strategies to ensure survival, enabling CSCs to modulate their metabolic pathways and contribute to cancer progression [37]. Lipid metabolism intersects with amino acid metabolism, highlighting the intricate adaptations cancer cells use to sustain growth [33]. Targeting these metabolic vulnerabilities offers therapeutic avenues to inhibit tumor growth and prevent recurrence and metastasis [38].

5.3 Metabolic Interactions with the Tumor Microenvironment

The tumor microenvironment (TME) significantly influences cancer metabolism and progression. Metabolic interactions within the TME provide essential nutrients and modulate cellular signaling pathways. Fatty acids are critical in these interactions, promoting tumor progression and metastasis [35]. The availability and utilization of fatty acids affect cancer cell behavior, emphasizing lipid metabolism's importance in cancer biology. Research has identified key enzymes in lipid metabolism correlating with cancer aggressiveness, offering insights into potential therapeutic targets [34]. These enzymes facilitate the metabolic reprogramming necessary for cancer cell adaptation to nutrient-deprived conditions in the TME, allowing survival despite environmental stresses and therapeutic interventions [31]. By modulating lipid pathways, cancer cells maintain energy balance and biosynthetic capacity, supporting tumor growth.

The interplay between metabolic changes and the TME underscores the importance of understanding cancer cell metabolic dependencies. As cancer cells manipulate their interactions with the TME, particularly through nutrient metabolism like glutamine utilization, targeting these vulnerabilities emerges as a promising therapeutic strategy. This approach aims to exploit adaptations cancer cells make to maintain proliferation and evade immune responses, offering potential avenues for effective treatment [30, 39, 40].

5.4 Epigenetic Regulation and Metabolic Reprogramming

The relationship between epigenetic regulation and metabolic reprogramming in cancer cells is crucial for understanding adaptive mechanisms driving tumor progression and therapeutic resistance. Epigenetic modifications, such as DNA methylation and histone acetylation, modulate gene expression patterns governing metabolic pathways, influencing cancer cell metabolism and survival [30]. These modifications can activate or suppress key metabolic genes, facilitating the flexibility required for cancer cells to thrive in nutrient-deprived and hypoxic environments [21].

Metabolic reprogramming in cancer involves significant changes in lipid, glucose, and amino acid metabolism, often regulated by epigenetic mechanisms [33]. The PI3K-AKT pathway, frequently dysregulated in cancers, influences both lipid metabolism and epigenetic states, suggesting potential therapeutic targets that exploit these vulnerabilities. The interplay between PI3K-AKT signaling and metabolic pathways indicates the potential for combination therapies targeting both signaling and metabolic dependencies to enhance efficacy.

Recent studies emphasize the role of m6A RNA methylation in metabolic reprogramming, influencing processes such as transcription, translation, and mRNA stability. This epigenetic modification emerges as a promising target for regulating cancer metabolism and improving treatment outcomes [41, 25, 39, 42, 30]. By modulating the stability and translation of mRNAs encoding metabolic enzymes, m6A methylation impacts various metabolic processes, including lipid metabolism. Additionally, the regulation of cancer metabolism by circRNAs offers new therapeutic intervention opportunities.

Integrating epigenetic regulation with metabolic reprogramming is vital for developing targeted cancer therapies. Understanding the control principles governing metabolic networks and their interactions with gene regulation and signaling pathways can reveal therapeutic vulnerabilities and facilitate targeted interventions to improve treatment outcomes across cancer types [43, 44, 45, 36, 30]. Pharmacological strategies targeting glutamine metabolism are currently under investigation, with clinical trials exploring the efficacy of potential therapeutic agents aimed at exploiting cancer cell metabolic dependencies to impair tumor growth and overcome treatment resistance.

5.5 Role of p53 in Cancer Metabolism

The p53 protein is crucial in regulating cancer metabolism, mediating cellular responses to metabolic stress and influencing essential pathways for cancer cell survival and proliferation. As a tumor suppressor, p53 modulates gene expression involved in glycolysis, oxidative phosphorylation, and lipid metabolism, maintaining metabolic homeostasis and preventing oncogenic transformation [38].

A key function of p53 is to modulate glycolytic flux. Under metabolic stress, p53 regulates energy metabolism by promoting oxidative phosphorylation while inhibiting glycolysis. This shift facilitates more efficient energy production, counteracting the Warburg effect observed in cancer cells, which typically rely on glycolysis. By enhancing oxidative phosphorylation, p53 supports ATP generation and modulates pathways implicated in cancer growth and resistance [17, 41, 18]. This not only meets cellular energy needs but also limits the availability of glycolytic intermediates for anabolic processes, constraining cancer cell proliferation.

In addition to glucose metabolism, p53 influences lipid metabolism by regulating genes involved in fatty acid oxidation and synthesis, impacting lipid homeostasis and energy balance. This regulation highlights how cancer cells adapt their lipid metabolism under stress, suggesting therapeutic targeting of these pathways to improve outcomes [38]. By modulating lipid metabolism, p53 helps maintain membrane integrity and produce critical signaling molecules for cellular adaptation and survival.

p53 also plays a critical role in amino acid metabolism, particularly in glutamine uptake and utilization, vital for cancer cell proliferation and survival. This regulation is crucial for maintaining redox balance and supporting the anabolic demands of rapidly dividing cancer cells [46, 39]. By controlling glutamine metabolism, p53 supports redox balance and biosynthetic processes essential for tumor progression.

Due to its role in orchestrating cancer metabolism and reversing the Warburg effect, p53 is a promising therapeutic target. It regulates the metabolic shift in cancer cells from glycolysis to oxidative phosphorylation, addressing the alterations driving uncontrolled growth and resistance to therapies. Enhancing p53 activity may trigger apoptosis following chemotherapy and modify metabolic pathways linked to treatment resistance, suggesting that strategies aimed at restoring p53 function could

effectively combat cancer by normalizing metabolic processes [17, 18, 39]. Understanding p53's multifaceted role in cancer metabolism could lead to novel therapeutic approaches that exploit cancer cell metabolic vulnerabilities.

6 Therapeutic Targets and Strategies

6.1 Epigenetic Modifications as Therapeutic Targets

Targeting epigenetic modifications offers a promising avenue in cancer therapy, particularly for addressing cancer stem cells (CSCs) and their roles in tumor recurrence and therapy resistance. The reversible nature of epigenetic changes, such as acetylation and methylation, provides a means to modulate gene expression pivotal for cancer progression [8]. Histone deacetylase (HDAC) inhibitors have shown potential in reactivating tumor suppressor genes, notably in hepatocellular carcinoma (HCC) [8]. Emerging strategies focus on histone acyl-PTMs regulated by acyl-CoA concentrations to disrupt epigenetic control mechanisms that maintain CSC properties [8]. However, due to the potential for non-CSCs to revert to a CSC state, comprehensive strategies addressing tumor heterogeneity are necessary [10]. Multi-target therapies are being explored to enhance treatment efficacy by targeting CSCs specifically. Ongoing clinical trials reveal complexities in their design, emphasizing the need for nuanced strategies [4]. Future research should refine therapeutic models to incorporate additional variables and strategies addressing heterogeneity [11]. By leveraging insights into gene regulatory networks, signaling pathways, and metabolic dependencies, targeted therapies can be developed to selectively eliminate cancer cells and overcome resistance, improving patient outcomes.

6.2 Targeting Lipid Metabolism and Modifications

Targeting lipid metabolism is a promising strategy in cancer therapy, given its vital role in cancer cell survival, proliferation, and metastasis. Cancer cells reprogram lipid metabolism, increasing lipogenesis and lipid uptake to support rapid cell division and tumor growth [35]. Disrupting these pathways can impair cancer cell viability and reduce tumor progression. Key enzymes in lipid biosynthesis, like fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), are often upregulated in cancer cells [34]. Inhibitors targeting these enzymes have shown efficacy in preclinical models, reducing lipid synthesis and inducing apoptosis. Targeting the PI3K-AKT signaling pathway, which regulates lipid metabolism, is another therapeutic strategy, as its aberrant activation enhances lipid synthesis and storage, supporting growth and survival [36]. Targeting lipid modification processes, such as protein acylation, can disrupt cancer cell signaling and survival [8]. The interplay between lipid metabolism and the tumor microenvironment (TME) presents further therapeutic opportunities. Cancer cells exploit lipid pathways to adapt to nutrient-deprived conditions within the TME, suggesting therapies targeting these adaptations could be beneficial [35]. Continued research into lipid metabolism mechanisms in cancer cells is essential for developing targeted strategies that exploit vulnerabilities associated with altered lipid pathways. Recent studies emphasize the role of lipid metabolic reprogramming in cancer metastasis, revealing adaptations in lipid synthesis and uptake in response to metabolic stress, crucial for membrane biogenesis, energy production, and survival in challenging tumor microenvironments. Understanding specific enzymes and lipid structures involved, such as fatty acid synthase and lipid rafts, could lead to innovative treatments that disrupt these adaptations and inhibit tumor progression [38, 34].

6.3 Combination Therapies Targeting mTOR and Metabolic Dependencies

The mammalian target of rapamycin (mTOR) pathway is a critical target in cancer therapy due to its role in regulating cell growth, proliferation, and metabolism. mTOR signaling integrates environmental cues, including nutrient availability and growth factors, to modulate processes essential for cancer cell survival and growth [36]. Dysregulation of the mTOR pathway is common in cancer, contributing to enhanced anabolic processes and metabolic reprogramming that support tumor progression and resistance to therapy. Combination therapies targeting mTOR and metabolic dependencies offer a promising strategy to overcome monotherapy limitations and enhance therapeutic efficacy. By simultaneously targeting mTOR signaling and metabolic pathways such as glycolysis, lipid metabolism, and amino acid synthesis, these therapies aim to disrupt metabolic adaptations cancer cells rely on for survival [31]. This approach impairs cancer cell growth and addresses metabolic flexibility underlying treatment resistance. Integrating mTOR inhibitors with agents targeting specific metabolic pathways

has shown promise in preclinical models. For instance, combining mTOR inhibitors with glycolysis inhibitors effectively reduces cancer cell viability by limiting energy production and biosynthetic precursor availability [30]. Similarly, targeting lipid metabolic pathways alongside mTOR inhibition disrupts lipid biosynthesis and storage processes crucial for cancer cell proliferation and survival [35]. Combining mTOR inhibitors with therapies targeting the tumor microenvironment (TME) presents additional opportunities for enhancing treatment outcomes. By modulating metabolic interactions within the TME, these therapies can sensitize cancer cells to mTOR inhibition, improving therapeutic efficacy [34]. Developing combination therapies that exploit the interplay between mTOR signaling and metabolic dependencies represents a promising direction for cancer treatment, with potential to overcome resistance and improve patient outcomes.

6.4 Targeting Cancer Stem Cells and Their Microenvironment

Targeting cancer stem cells (CSCs) and their microenvironment is crucial for developing effective cancer therapies addressing tumor recurrence and resistance. The intricate interactions between CSCs and the tumor microenvironment (TME) necessitate strategies that disrupt both CSCs and their supportive niche [6]. The TME, composed of various cellular components such as mesenchymal stem cells (MSCs), plays a pivotal role in supporting CSC survival and proliferation [32]. Therapeutic approaches should aim to target specific TME components to enhance treatment efficacy [6]. Future research should focus on developing targeted therapies that specifically eliminate CSCs while minimizing effects on normal stem cells [15]. Disrupting the supportive roles of CSC niches can prevent non-CSCs from transitioning to CSCs, reducing tumor heterogeneity and relapse potential [22]. Understanding the differential metabolic requirements of immune cells within the TME allows researchers to selectively regulate their function in cancer therapy, offering opportunities to enhance therapeutic outcomes [32]. Integrating mathematical models capturing cell population dynamics based on self-renewal potential provides insights into interactions between normal and cancer cells, offering a framework for developing targeted therapies [6]. Exploring combination therapies incorporating insights from signaling networks, such as the Wnt pathway, could enhance treatment efficacy and reduce recurrence [6]. Focusing on both CSCs and their microenvironment, researchers can devise strategies to minimize resistance and improve patient outcomes.

6.5 Emerging Strategies and Future Directions

Cancer treatment strategies increasingly emphasize integrating metabolic reprogramming and targeted therapies to enhance therapeutic efficacy. A promising direction involves developing combination therapies incorporating mTOR inhibitors alongside agents targeting specific metabolic pathways, aiming to disrupt metabolic adaptations cancer cells depend on for survival [36]. These approaches address cancer cells' metabolic flexibility and tackle resistance mechanisms, potentially improving therapeutic outcomes [31]. Future research should explore detailed interactions between lipid metabolism and other pathways, investigating the therapeutic potential of lipid metabolic inhibitors in clinical settings [36]. Understanding these interactions is critical for developing targeted therapies exploiting cancer cells' metabolic vulnerabilities, reducing tumor progression and metastasis [33]. Identifying novel acylation sites and developing specific inhibitors to therapeutically manipulate acylation processes represent emerging strategies, underscoring epigenetic regulation's importance in cancer biology [42]. Exploring amino acid transporters and enzymes as therapeutic targets is another promising direction, with future research focusing on developing selective inhibitors considering tumor heterogeneity and metabolic flexibility [39]. This approach could lead to precise and effective cancer therapies tailored to specific metabolic dependencies of different cancer types [33]. Refining models quantifying underlying mechanisms and validating them with experimental results could lead to novel therapeutic interventions targeting identified regulatory mechanisms [47]. Integrating systems biology approaches and expanding network analyses to include more cancer types could refine the definition of cancer network cores, providing insights into potential therapeutic targets [13]. The role of circRNAs in cancer stem cell metabolism presents an exciting area for future research, with potential therapeutic applications targeting circRNAs to disrupt CSC function and reduce tumor growth [1]. Elucidating specific roles of arachidonic acid metabolites in various disease contexts could inform combination therapies targeting multiple pathways, enhancing treatment efficacy [29].

7 Conclusion

7.1 Clinical Significance and Treatment Resistance

Cancer stem cells (CSCs) are pivotal in cancer development and therapeutic resistance, underscoring the necessity for therapies targeting this resilient cell population. Their role in tumor heterogeneity is facilitated by unique biological traits such as enhanced DNA repair, quiescence, and self-renewal, enabling them to evade conventional treatments and contribute to recurrence. Thus, CSCs are critical targets for improving treatment outcomes. The identification of specific CSC markers is crucial for advancing diagnostic and therapeutic methods, allowing precise targeting of CSCs and their niches to enhance treatment efficacy. However, the lack of specificity in many studies results in incomplete tumor eradication and the persistence of drug-resistant populations. The tumor microenvironment plays a significant role in the efficacy of differentiation therapy, highlighting the need for strategies that address both CSCs and their microenvironmental context. Mitochondria, integral to cancer metabolism and therapeutic resistance, contribute to the metabolic reprogramming of CSCs, providing survival advantages under therapeutic stress. Disrupting these metabolic dependencies is essential for improving treatment outcomes. Additionally, aberrant Wnt signaling, particularly in breast cancer, complicates treatment resistance, as the intricate signaling networks in CSCs may activate compensatory mechanisms that hinder targeted therapy development. A comprehensive understanding of CSC biology, signaling pathways, and metabolic dependencies is crucial for devising effective therapeutic strategies to overcome resistance and improve patient survival.

7.2 Emerging Research and Unanswered Questions

Despite significant progress in CSC research, several critical questions remain unanswered, necessitating further exploration to refine therapeutic approaches. A key area of focus is identifying specific metabolic pathways that enhance immune responses and understanding the metabolic interactions between cancer and immune cells. These insights are vital for developing therapies that modulate the tumor microenvironment to support immune-mediated tumor eradication. The origins of CSCs and their mechanisms of therapy resistance present formidable challenges. Future research should delve into the spatio-temporal dynamics of CSCs in vivo and their phenotypic plasticity, which are central to tumor progression and therapy resistance. Incorporating feedback mechanisms and stochastic elements into existing models could enhance their biological relevance and predictive accuracy. Advanced computational techniques, such as network entropy analysis, offer promising avenues for investigating the temporal dynamics of CSC models in cancer, potentially addressing unresolved questions regarding CSC behavior and interactions. Understanding how various metabolites influence immune cell functions and effectively manipulating these pathways in therapy remain poorly understood areas. Future research should focus on elucidating these mechanisms, particularly the roles of specific metabolic pathways, like glutamine utilization across diverse cancer types, to translate findings into clinical practice. Additionally, unresolved questions persist regarding CSC-induced drug resistance and optimal strategies for targeting these cells. Addressing these questions through comprehensive research can significantly advance CSC research and contribute to developing innovative cancer therapies that improve patient outcomes and survival.

References

[1] Mariel E Toledo-Guzmán, Gabriele D Bigoni-Ordóñez, Miguel Ibáñez Hernández, and Elizabeth Ortiz-Sánchez. Cancer stem cell impact on clinical oncology. *World journal of stem cells*, 10(12):183, 2018.

[2] Kiyoung Eun, Seok Won Ham, and Hyunggee Kim. Cancer stem cell heterogeneity: origin and new perspectives on csc targeting. *BMB reports*, 50(3):117, 2017.

[3] Ain Zubaidah Ayob and Thamil Selvee Ramasamy. Cancer stem cells as key drivers of tumour progression. *Journal of biomedical science*, 25:1–18, 2018.

[4] Céline Hervieu, Niki Christou, Serge Battu, and Muriel Mathonnet. The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. *Cancers*, 13(5):1092, 2021.

[5] Xiao Ding, Weihua Zhang, Song Li, and Hui Yang. The role of cholesterol metabolism in cancer. *American journal of cancer research*, 9(2):219, 2019.

[6] Borros Arneth. Tumor microenvironment. *Medicina*, 56(1):15, 2019.

[7] Hamed Rezayatmand, Mahboobeh Razmkhah, and Iman Razeghian-Jahromi. Drug resistance in cancer therapy: the pandora's box of cancer stem cells. *Stem cell research & therapy*, 13(1):181, 2022.

[8] Johayra Simithy, Simone Sidoli, Zuo-Fei Yuan, Mariel Coradin, Natarajan V Bhanu, Dylan M Marchione, Brianna J Klein, Gleb A Bazilevsky, Cheryl E McCullough, Robert S Magin, et al. Characterization of histone acylations links chromatin modifications with metabolism. *Nature communications*, 8(1):1141, 2017.

[9] Peter Csermely, Janos Hodsagi, Tamas Korcsmaros, Dezso Modos, Aron R. Perez-Lopez, Kristof Szalay, Daniel V. Veres, Katalin Lenti, Ling-Yun Wu, and Xiang-Sun Zhang. Cancer stem cells display extremely large evolvability: alternating plastic and rigid networks as a potential mechanism, 2014.

[10] Pramudita R Prasetyanti and Jan Paul Medema. Intra-tumor heterogeneity from a cancer stem cell perspective. *Molecular cancer*, 16(1):41, 2017.

[11] Chong Yu, Qiong Liu, Cong Chen, and Jin Wang. A physical mechanism of heterogeneity in stem cell, cancer and cancer stem cell, 2019.

[12] Jerónimo Fotinós, Lucas Barberis, and Carlos A. Condat. Effects of a differentiating therapy on cancer-stem-cell-driven tumors, 2023.

[13] Matteo Turetta, Fabio Del Ben, Giulia Brisotto, Eva Biscontin, Michela Bulfoni, Daniela Cesselli, Alfonso Colombatti, Giacinto Scoles, Giuseppe Gigli, and Loretta L. del Mercato. Emerging technologies for cancer research: Towards personalized medicine with microfluidic platforms and 3d tumor models, 2021.

[14] Sahil D. Shah and Rosemary Braun. Network-based identification of disease genes in expression data: the genesurrounder method, 2019.

[15] Justin D Lathia and Huiping Liu. Overview of cancer stem cells and stemness for community oncologists. *Targeted oncology*, 12:387–399, 2017.

[16] Tan Boon Toh, Jhin Jieh Lim, and Edward Kai-Hua Chow. Epigenetics in cancer stem cells. *Molecular cancer*, 16:1–20, 2017.

[17] Tianshui Sun, Zhuonan Liu, and Qing Yang. The role of ubiquitination and deubiquitination in cancer metabolism. *Molecular cancer*, 19(1):146, 2020.

[18] Roba Abukwaik, Elias Vera-Siguenza, Daniel Tennant, and Fabian Spill. P53 orchestrates cancer metabolism: Unveiling strategies to reverse the warburg effect, 2024.

[19] Xiufang Chen, Yue Wang, Tianquan Feng, Ming Yi, Xingan Zhang, and Da Zhou. The overshoot and phenotypic equilibrium in characterizing cancer dynamics of reversible phenotypic plasticity, 2015.

[20] Mohammed H. Rashed, Emine Bayraktar, Gouda K. Helal, Mohamed F Abd-Ellah, Paola Amero, Arturo Chavez-Reyes, and Cristian Rodriguez-Aguayo. Exosomes: from garbage bins to promising therapeutic targets. *International journal of molecular sciences*, 18(3):538, 2017.

[21] Longzheng Xia, Linda Oyang, Jinguan Lin, Shiming Tan, Yaqian Han, Nayiyuan Wu, Pin Yi, Lu Tang, Qing Pan, Shan Rao, et al. The cancer metabolic reprogramming and immune response. *Molecular cancer*, 20:1–21, 2021.

[22] Marta Prieto-Vila, Ryou-u Takahashi, Wataru Usuba, Isaku Kohama, and Takahiro Ochiya. Drug resistance driven by cancer stem cells and their niche. *International journal of molecular sciences*, 18(12):2574, 2017.

[23] Nasir Javaid and Sangdun Choi. Acetylation-and methylation-related epigenetic proteins in the context of their targets. *Genes*, 8(8):196, 2017.

[24] He Huang, Di Zhang, Yi Wang, Mathew Perez-Neut, Zhen Han, Y George Zheng, Quan Hao, and Yingming Zhao. Lysine benzoylation is a histone mark regulated by sirt2. *Nature communications*, 9(1):3374, 2018.

[25] Miaomiao Huo, Jingyao Zhang, Wei Huang, and Yan Wang. Interplay among metabolism, epigenetic modifications, and gene expression in cancer. *Frontiers in Cell and Developmental Biology*, 9:793428, 2021.

[26] Ahmad A Cluntun, Michael J Lukey, Richard A Cerione, and Jason W Locasale. Glutamine metabolism in cancer: understanding the heterogeneity. *Trends in cancer*, 3(3):169–180, 2017.

[27] Xiufang Xu, Miaofeng Zhang, Faying Xu, and Shaojie Jiang. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. *Molecular cancer*, 19(1):165, 2020.

[28] Alice Turdo, Veronica Veschi, Miriam Gaggianesi, Aurora Chinnici, Paola Bianca, Matilde Todaro, and Giorgio Stassi. Meeting the challenge of targeting cancer stem cells. *Frontiers in cell and developmental biology*, 7:16, 2019.

[29] Wesley F Taylor and Ehsan Jabbarzadeh. The use of natural products to target cancer stem cells. *American journal of cancer research*, 7(7):1588, 2017.

[30] Haoxin Li, Shaoyang Ning, Mahmoud Ghandi, Gregory V Kryukov, Shuba Gopal, Amy Deik, Amanda Souza, Kerry Pierce, Paula Keskula, Desiree Hernandez, et al. The landscape of cancer cell line metabolism. *Nature medicine*, 25(5):850–860, 2019.

[31] Jae Hyung Park, Woo Yang Pyun, and Hyun Woo Park. Cancer metabolism: phenotype, signaling and therapeutic targets. *Cells*, 9(10):2308, 2020.

[32] Robert D Leone and Jonathan D Powell. Metabolism of immune cells in cancer. *Nature reviews cancer*, 20(9):516–531, 2020.

[33] Lisa Vettore, Rebecca L Westbrook, and Daniel A Tennant. New aspects of amino acid metabolism in cancer. *British journal of cancer*, 122(2):150–156, 2020.

[34] Xiangjian Luo, Can Cheng, Zheqiong Tan, Namei Li, Min Tang, Lifang Yang, and Ya Cao. Emerging roles of lipid metabolism in cancer metastasis. *Molecular cancer*, 16(1):76, 2017.

[35] Nikos Koundouros and George Poulogiannis. Reprogramming of fatty acid metabolism in cancer. *British journal of cancer*, 122(1):4–22, 2020.

[36] Gerta Hoxhaj and Brendan D Manning. The pi3k–akt network at the interface of oncogenic signalling and cancer metabolism. *Nature Reviews Cancer*, 20(2):74–88, 2020.

[37] Aleksandra Ardaševa, Robert A. Gatenby, Alexander R. A. Anderson, Helen M. Byrne, Philip K. Maini, and Tommaso Lorenzi. Evolutionary dynamics of competing phenotype-structured populations in periodically fluctuating environments, 2019.

[38] Rimsha Munir, Jan Lisec, Johannes V Swinnen, and Nousheen Zaidi. Lipid metabolism in cancer cells under metabolic stress. *British journal of cancer*, 120(12):1090–1098, 2019.

[39] Yeon-Kyung Choi and Keun-Gyu Park. Targeting glutamine metabolism for cancer treatment. *Biomolecules & therapeutics*, 26(1):19, 2017.

[40] Inmaculada Martínez-Reyes and Navdeep S Chandel. Cancer metabolism: looking forward. *Nature Reviews Cancer*, 21(10):669–680, 2021.

[41] Dirk Mossmann, Sujin Park, and Michael N Hall. mtor signalling and cellular metabolism are mutual determinants in cancer. *Nature Reviews Cancer*, 18(12):744–757, 2018.

[42] Yuanyuan An and Hua Duan. The role of m6a rna methylation in cancer metabolism. *Molecular cancer*, 21(1):14, 2022.

[43] Georg Basler, Zoran Nikoloski, Abdelhalim Larhlimi, Albert-László Barabási, and Yang-Yu Liu. Control principles of metabolic networks, 2015.

[44] Bhanwar Lal Puniya, Laura Allen, Colleen Hochfelder, Mahbubul Majumder, and Tomáš Helikar. Systems perturbation analysis of a large scale signal transduction model reveals potentially influential candidates for cancer therapeutics, 2015.

[45] Michael A. Kochen, Steven S. Andrews, H. Steven Wiley, Song Feng, and Herbert M. Sauro. Dynamics and sensitivity of signaling pathways, 2021.

[46] Elizabeth L Lieu, Tu Nguyen, Shawn Rhyne, and Jiyeon Kim. Amino acids in cancer. *Experimental & molecular medicine*, 52(1):15–30, 2020.

[47] Da Zhou, Yue Wang, and Bin Wu. A multi-phenotypic cancer model with cell plasticity, 2014.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.